In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Evidence, effectiveness and practical implications
Medicinal plants for allergic rhinitis
- Current status and future prospects
Cell and gene therapies in modern cardiology
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people